Published in J Med Case Rep on November 30, 2012
Herbal medicine and acupuncture for breast cancer palliative care and adjuvant therapy. Evid Based Complement Alternat Med (2013) 0.90
Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res (2014) 0.83
Ferulic Acid against Cyclophosphamide-Induced Heart Toxicity in Mice by Inhibiting NF-κB Pathway. Evid Based Complement Alternat Med (2016) 0.79
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol (2009) 4.56
Severe interstitial pneumonitis associated with docetaxel administration. Cancer (2002) 1.34
Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med (1996) 1.27
Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br J Cancer (2001) 1.20
Docetaxel and interstitial pulmonary injury. Ann Oncol (1997) 1.09
Severe interstitial pneumonitis associated with the administration of taxanes. J Infect Chemother (2010) 1.07
Fatal pneumonitis after treatment with docetaxel and trastuzumab. Neth J Med (2009) 1.02
Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res (2012) 0.97
Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone-refractory prostate cancer. Tumori (2007) 0.97
High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer (2004) 0.95
Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. Am J Ther (2003) 0.90
Novel cytotoxic drugs: old challenges, new solutions. Cancer Treat Rev (2007) 0.88
Bronchiolitis obliterans organizing pneumonia simulating progression in bronchioloalveolar carcinoma. Clin Transl Oncol (2006) 0.87
Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature. Bone Marrow Transplant (2001) 0.85
Acute lung injury associated with docetaxel and bevacizumab. Clin Oncol (R Coll Radiol) (2007) 0.82
Pneumonitis related to docetaxel: case report and review of the literature. In Vivo (2009) 0.80
Acute interstitial pneumopathy associated with docetaxel hypersensitivity. Onkologie (2004) 0.79
Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients. J Oncol Pharm Pract (2012) 0.79
Severe Organizing Pneumonia after Two Cycles of Docetaxel as Fourth-Line Chemotherapy for Advanced Non-Small Cell Carcinoma of the Lung. Case Rep Oncol (2009) 0.79
Ubiquitin-positive pneumocytes and inclusion bodies are present in secondary organizing pneumonia. Intern Med (2011) 0.78
Docetaxel-induced fatal interstitial pneumonitis in a patient with castration-resistant prostate cancer. Korean J Urol (2012) 0.78
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (2011) 2.03
How stress management improves quality of life after treatment for breast cancer. J Consult Clin Psychol (2006) 1.81
Fighting fire with fire: rekindling the bevacizumab debate. N Engl J Med (2012) 1.69
Lymphoepithelial cysts of the pancreas: a report of 12 cases and a review of the literature. Mod Pathol (2002) 1.65
Vulvar Langerhans cell histiocytosis: a case report and review of the literature. Gynecol Oncol (2003) 1.43
Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma. Arch Surg (2010) 1.39
A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol (2013) 1.30
Stress management intervention reduces serum cortisol and increases relaxation during treatment for nonmetastatic breast cancer. Psychosom Med (2008) 1.27
Treating breast cancer in the 21st century: emerging biological therapies. J Cancer (2013) 1.26
Low-grade fibromyxoid sarcoma: a brief review. Arch Pathol Lab Med (2006) 1.25
Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer (2013) 1.23
Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat (2013) 1.21
Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr Oncol Rep (2012) 1.17
Large esophageal liposarcoma: a case report and review of the literature. Arch Pathol Lab Med (2004) 1.17
Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol (2008) 1.14
A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer (2009) 1.14
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat (2010) 1.14
TLR4 activates the β-catenin pathway to cause intestinal neoplasia. PLoS One (2013) 1.10
Participation in cancer clinical trials: why are patients not participating? Med Decis Making (2013) 1.10
Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes Control (2009) 1.08
Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med (2013) 1.05
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Res Treat (2014) 1.05
Hedgehog-producing cancer cells respond to and require autocrine Hedgehog activity. Cancer Res (2011) 1.05
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer (2012) 1.05
Acceleration of telomere loss by chemotherapy is greater in older patients with locally advanced head and neck cancer. Clin Cancer Res (2006) 1.02
Upper gastrointestinal tumors: current status and future perspectives. Expert Rev Anticancer Ther (2008) 1.01
Primary ectopic breast cancer presenting as a vulvar mass. Clin Breast Cancer (2006) 1.01
Ameloblastic carcinosarcoma of the mandible arising in ameloblastic fibroma: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2006) 1.01
Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics (2014) 0.98
Adjuvant and preoperative therapy for localized gastric cancer. Gastrointest Cancer Res (2007) 0.97
Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer (2011) 0.95
Systemic therapy options in BRCA mutation-associated breast cancer. Breast Cancer Res Treat (2012) 0.95
Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model. Cancer Immunol Immunother (2007) 0.95
Cystic lesions of the pancreas: clinical and pathologic review of cases in a five year period. JOP (2010) 0.94
Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation (2004) 0.94
Histopathological changes after microwave coagulation therapy for patients with hepatocellular carcinoma: review of 15 explanted livers. Am J Gastroenterol (2003) 0.91
Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl (2004) 0.91
Eosinophilic cholangiopathy with concurrent eosinophilic colitis in a patient with idiopathic hypereosinophilic syndrome. Eur J Gastroenterol Hepatol (2008) 0.91
Adenomyomatous hyperplasia of the gallbladder with perineural invasion: revisited. Am J Surg Pathol (2007) 0.91
Successful treatment of anal gland adenocarcinoma with combined modality therapy. Gastrointest Cancer Res (2012) 0.90
A retrospective review of sirolimus (Rapamune) therapy in orthotopic liver transplant recipients diagnosed with chronic rejection. Liver Transpl (2003) 0.90
Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Expert Rev Clin Pharmacol (2011) 0.90
A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res Treat (2011) 0.90
Oncocytic papillary neoplasms of the biliary tract: a clinicopathological, mucin core and Wnt pathway protein analysis of four cases. Pathology (2007) 0.89
Sleep quality and fatigue after a stress management intervention for women with early-stage breast cancer in southern Florida. Int J Behav Med (2014) 0.89
Optimizing imatinib mesylate treatment in gastrointestinal stromal tumors. Gastrointest Cancer Res (2008) 0.88
Tumor of the liver (hepatocellular and high grade neuroendocrine carcinoma): a case report and review of the literature. Virchows Arch (2006) 0.87
Interferon-gamma suppresses cyclooxygenase-2 promoter activity by inhibiting C-Jun and C/EBPbeta binding. Arterioscler Thromb Vasc Biol (2007) 0.86
Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treat Rev (2011) 0.86
Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy. Med Oncol (2014) 0.86
Gemcitabine and taxanes in metastatic breast cancer: a systematic review. Ther Clin Risk Manag (2008) 0.85
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study. Expert Opin Investig Drugs (2013) 0.85
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer. Breast Cancer Res Treat (2012) 0.84
Chemoprevention of breast cancer. Expert Rev Anticancer Ther (2008) 0.84
Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma. Cancer Biol Ther (2007) 0.84
Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma: outcome after liver transplantation. Dig Dis Sci (2010) 0.84
Exemestane in the adjuvant treatment of breast cancer in postmenopausal women. Breast Cancer (Auckl) (2011) 0.83
Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. J Support Oncol (2010) 0.83
Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer? Expert Opin Ther Targets (2012) 0.83
Right trisectionectomy of the liver for intrahepatic cholangiocarcinoma with bile duct invasion in a Jehovah's Witness. J Hepatobiliary Pancreat Surg (2007) 0.83
Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer. Case Rep Oncol (2012) 0.83
Pseudocavitating bronchioloalveolar carcinoma followed over a decade. Ann Thorac Surg (2008) 0.83
The glutathione disulfide mimetic NOV-002 inhibits cyclophosphamide-induced hematopoietic and immune suppression by reducing oxidative stress. Free Radic Biol Med (2012) 0.82
Comparison of CD34 and monocyte-derived dendritic cells from mobilized peripheral blood from cancer patients. Stem Cells (2005) 0.82
In silico and Ex vivo approaches identify a role for toll-like receptor 4 in colorectal cancer. J Exp Clin Cancer Res (2014) 0.82
Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung (2009) 0.82
Intraductal oncocytic papillary neoplasm of the extrahepatic biliary tree: first report. Am Surg (2004) 0.82
Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers? Breast Cancer Res Treat (2014) 0.81
Correlation of Laparoscopic Liver Biopsy to Elasticity Measurements (FibroScan) in Patients With Chronic Liver Disease. Gastroenterol Hepatol (N Y) (2008) 0.81
Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat (2014) 0.81
Examination of Surgical Specimens of the Esophagus. Arch Pathol Lab Med (2015) 0.81
Clinical outcomes in breast cancer patients with HIV/AIDS: a retrospective study. Breast Cancer Res Treat (2015) 0.79
Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy. Breast Cancer (Auckl) (2012) 0.79
Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. Breast Cancer Res Treat (2010) 0.79
Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer (2007) 0.78
Prospective Evaluation of FIBROSpect II for Fibrosis Detection in Hepatitis C and B Patients Undergoing Laparoscopic Biopsy. Gastroenterol Hepatol (N Y) (2007) 0.78
Postsurgical Depressive Symptoms and Proinflammatory Cytokine Elevations in Women Undergoing Primary Treatment for Breast Cancer. Psychosom Med (2016) 0.78
Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma. Med Oncol (2011) 0.78
Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer (2007) 0.78
Imatinib mesylate (gleevec) hepatotoxicity. Dig Dis Sci (2007) 0.77
Gene expression profiling in breast cancer. Am J Transl Res (2013) 0.77
Tacrolimus induced hepatotoxicity in a patient with bilateral lung transplant. Transpl Int (2012) 0.77
Macrophages as independent prognostic factors in small T1 breast cancers. Oncol Rep (2012) 0.77
Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients. Med Oncol (2004) 0.77
A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer. Breast Cancer Res Treat (2013) 0.77
A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer. Breast Cancer Res Treat (2014) 0.76
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Invest New Drugs (2014) 0.76
A case of severe thrombotic thrombocytopenic purpura with concomitant Legionella pneumonia: review of pathogenesis and treatment. Am J Ther (2011) 0.76
Synergy of brief activation of CD8 T-cells in the presence of IL-12 and adoptive transfer into lymphopenic hosts promotes tumor clearance and anti-tumor memory. Am J Cancer Res (2011) 0.76
Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. Arch Intern Med (2003) 0.75
Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L. Immunol Res (2013) 0.75